Introduction

Acyl-Coenzyme: A Cholesterol Acyltransferase 1 (ACAT1), or also known as Sterol O-Acyltransferase (SOAT), is an important enzyme in the body. ACAT is an important enzyme that catalyzes the esterification of cholesterol to form cholesterol esters, and it belongs to the class of enzymes called acyltransferases (Figure 1). As a member of the MBOAT family, it is a key enzyme in lipid metabolism. This enzyme is biologically important because it affects the solubility of cholesterol in the cell membrane and promotes accumulation of cholesterol ester in the cytoplasm as fat droplets. Accumulation of cholesterol ester as these lipid droplets is a main characteristic of macrophage foaming, which can lead to atherosclerotic diseases ^[1]. Cholesterol esters were found in arterial lesions in 1910, but the first ACAT activity was discovered in the mid 1900's. This led to the inhibition of ACAT as being looked at as a possible strategy of preventing or treating atherosclerosis. Between 1980-1995, the interest in ACAT inhibitors grew, but some of the compounds developed exhibited toxicity. As they were looking into the function of the ACAT1 gene, ACAT2 was discovered. In 1993, an ACAT gene was successfully cloned. This discovery led to more studies with ACAT and atherosclerosis. Some of these studies used mice and also showed cellular toxicity. ACAT inhibition is still being pursued as a strategy for treatment or prevention of atherosclerosis and related diseases. ^[2]

Figure 1. Chemical Structures for the Reactants and Products of ACAT1

Structural Overview

ACAT1 was experimentally determined as a tetramer of size approximately 260 kDa, composed of helices and loops. Each monomer of the tetramer contains 9 transmembrane helices (Figure 3). However, the dimer of ACAT1 was found to be the biologically active arrangement.

This is about 260 kDa and is composed of helices and loops, with each monomer containing 9 transmembrane helices (Figure 3). The was found to be the active arrangement.

Figure 2. ACAT1 Dimer in the Membrane. The gray shaded region is the plane of the bilipid membrane. The tunnels where molecules enter and exit are labeled. The ER lumen is at the top with the cytosol at the bottom.

Dimer-Dimer Interface

The is mobile and mostly hydrophobic, and the residues interact in a shape-complementary manner. It was also found that the reaction chamber is shielded by a lid from the cytosolic side, which leads to low catalytic activity. The binding of acyl-CoA and cholesterol induce conformational changes that activate the tunnels necessary for substrates to enter them. Work is still being done to fully determine the mechanism of this reaction, but this is the proposed pathway.

Figure 3. ACAT1 Monomer in the Membrane. This shows the 9 transmembrane helices. Each helix is labeled and colored according to the different domains. The ligand is shown as ball and stick.

Tunnels

The catalytic site is accessed through three different tunnels that lead from the center catalytic chamber of the monomer, to the lumen, cytosol, and transmembrane spaces. The tunnels allow the introduction of reactants into the acyl transferase mechanism and the exit of the products to the correct location depending on their function. The cholesterol enters through the T tunnel while the acyl-CoA enters through the C tunnel. The is open to the cytosolic side of the protein in which the Acyl Co-A enters into the catalytic chamber. The is the transmembrane tunnel in which the cholesterol enters into the catalytic region. Important include Arg262, Phe263, and Leu306. These residues are important for the proper entrance and orientation of the cholesterol to allow for its deprotonation in the mechanism. Upon mutation of these residues, the tunnel function was inhibited. The provides a potential opening to the lumen side. The enzymatic reaction occurs at the intersection of these two tunnels. It is catalyzed at the intersection of the two tunnels, where the His460 residue is located. The CoASH is released to the cytosol by way of the C tunnel, but the cholesterol ester either exits from the T tunnel to the membrane or through the L tunnel to the lumen. The specific mechanism by which the cholesterol ester product exits the tunnel to enter the lumen has not yet been determined.

Active Site

The active site contains that are essential to the ACAT1 mechanism. These residues include His460 to function as a base catalyst and Asn421 which functions as transition state stabilization with hydrogen bonding. Also important for orientation of the Acyl Co-A ligand is the presence of hydrophobic residues (Trp407,Trp420) to stabilize the fatty acid. The active site is at the intersection of all three tunnels to allow a central position for the acyltransferase reaction to occur. The His460 is positioned to deprotonate the cholesterol upon entrance into the T tunnel: Acyl Co-A upon entering is positioned to where the sulfur bonded to the carboxyl carbon is at the direct intersection of the T tunnel into the active site.

Mechanism

The mechanism of the [acyltransferace]reaction occurs in the catalytic site of each monomer of the dimer of ACAT1. The T and and C tunnels converge to the same space to allow the proper orientation of the Acyl Co-A and the incoming cholesterol from the transmembrane. The Acyl Co-A is oriented in a way to allow the His460 to act as a base catalyst to begin the reaction by deprotonation of the cholesterol, which allows it to attack the carbonyl carbon which breaks the sulfur carbonyl bond (Figure 4). The Acyl CoA transition state is held in place by the of Asn421. This mechanism produces Acyl-CoASH and cholesterol ester. The Acyl-CoASH leaves through the C tunnel to the cytosol.

Figure 4: Acyltransferase mechanism of ACAT1 with conserved MBOAT family catalytic residues.

Inhibitor

is known as a small molecule inhibitor that is part of what is called the fatty acyl amide analog family, and functions as a competitive inhibitor of Acyl Co-A ^[3][4]. Guan discussed that this inhibitor in previous studies had shown that CI-976 reduced the size of atherosclerotic plaques and cholesterol levels in plasma ^[4] .

Figure 5. CI-976 Inhibitor

Diseases

Neurodegenerative Diseases and Cancers

ACAT is involved in diseases such as Alzheimer's Disease and Parkinson’s Disease and other neurodegenerative diseases due to the accumulation of Aβ plaques in the brain. After research on glioma, prostate cancer, pancreatic cancer, leukemia, and breast cancer, it has been noted that ACAT plays a role in the progression of cancer over time. Recently, Ayyagari et al. found that there was a significant increase in ACAT1 expression in ovarian cancer cell lines ^[5]. ACAT-2 is believed to be upregulated in Nephrotic Syndrome which can lead to cardiovascular disease and renal diseases ^[6]. Because of ACAT's activity in tissues such as the aorta, intestine, and liver, it plays a role in atherosclerosis. Studies have shown that the inhibition of ACAT2 can slow the progression of Atherosclerosis ^[7]. Guan discussed a previous study which found that CI-976 decreased the size of atherosclerosis plaques and the overall concentration of cholesterol in the blood plasma of animals that had been fed a high cholesterol diet ^[4]

Alzheimer's Disease

Alzheimer's Diseaseis a neurodegenerative disease characterized by accumulation of extracellular plaques that cause interferences with memory retrieval. These plaques are made up of Amyloid Beta (Aβ) peptides which are products of the cleavage of Human Amyloid-Beta Precursor Protein (hAPP) ^{[8] [9]}. Within the cells, there is an accumulation of hyperphosphorylated Tau protein ^{[8] [9]}. Research has shown that the concentration of cholesterol within cells can affect the production of Aβ ^{[8] [9]}. As the concentration of cholesterol in the endoplasmic reticulum of neurons increases, hAPP is downregulated ^[8][9]. Inhibition of ACAT1 would lead to higher concentrations of cholesterol in the cells, signaling downregulation of hAPP. Less hAPP available decreases the amount of Aβ peptides being produced which then reduces the available Aβ peptides that form the extracellular plaques associated with Alzheimer's Disease ^{[8] [9]}.